MHRA-2022-0008-V308

Type II variation for application MHRA-2022-0008. Type II variation: New Dosage Strength for Alzabistat — major revision

Variation Number
MHRA-2022-0008-V308
Type
Type II
Application
MHRA-2022-0008
Change
CHG-2021-0008
Status
Active
Fee
€27,057
Submitted
2023-12-18
Approved
—
Description

Type II variation: New Dosage Strength for Alzabistat — major revision